{"id":18603,"date":"2026-06-02T12:14:11","date_gmt":"2026-06-02T12:14:11","guid":{"rendered":"https:\/\/www.europesays.com\/be\/18603\/"},"modified":"2026-06-02T12:14:11","modified_gmt":"2026-06-02T12:14:11","slug":"belgium-ucb-completes-acquisition-of-neurona-therapeutics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/be\/18603\/","title":{"rendered":"Belgium: UCB completes acquisition of Neurona Therapeutics"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Euronext-listed UCB, a Belgium-based global biopharmaceutical company, has acquired Neurona Therapeutics, a US-based clinical-stage biotherapeutics company developing regenerative cell therapies, for a total transaction valued of up to US$1.15bn consisting of a US$650m upfront payment plus up to US$500m in potential future milestone payments.<\/p>\n<p class=\"wp-block-paragraph\">The transaction, which includes Neurona\u2019s lead asset rezanecel \u2013 an investigational drug under phase l\/ll investigation for drug-resistant mesial temporal lobe epilepsy \u2013 adds to UCB\u2019s epilepsy portfolio and accelerates UCB\u2019s entry into next-generation disease-modifying therapies and cell therapies.<\/p>\n<p class=\"wp-block-paragraph\">Press release: <a href=\"https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/ucb-completes-acquisition-of-neurona-therapeutics-advancing-its-leadership-as-innovator-in-epilepsy-through-regenerative-science\" rel=\"nofollow noopener\" target=\"_blank\">UCB completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science | UCB<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Euronext-listed UCB, a Belgium-based global biopharmaceutical company, has acquired Neurona Therapeutics, a US-based clinical-stage biotherapeutics company developing regenerative&hellip;\n","protected":false},"author":2,"featured_media":18604,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[7,12060,9405],"class_list":["post-18603","post","type-post","status-publish","format-standard","has-post-thumbnail","category-belgium","tag-belgium","tag-neurona-therapeutics","tag-ucb"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@be\/116680462537168706","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts\/18603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/comments?post=18603"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts\/18603\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/media\/18604"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/media?parent=18603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/categories?post=18603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/tags?post=18603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}